You are here

  • Home
  • Online First
  • Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

Article metrics

Article menu

This article has corrections. Please see:

other Versions

Download PDFPDF
Clinical trial
Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer

 

Online download statistics by month:

Online download statistics by month: December 2019 to April 2024

AbstractFullPdf
Dec 201922569
Jan 20203223017
Feb 2020367156
Mar 202016489
Apr 2020147168
May 20205292013
Jun 2020147107
Jul 202098117
Aug 20207933
Sep 20208042
Oct 20205440
Nov 20209682
Dec 202010821
Jan 202120384
Feb 20217512
Mar 202115311
Apr 202111330
May 20213855
Jun 2021421
Jul 2021311
Aug 2021710
Sep 2021974
Oct 20214522
Nov 20216800
Dec 202111461
Jan 20226020
Feb 20226421
Mar 202219354
Apr 202212123
May 20227700
Jun 20228742
Jul 20225743
Aug 202211240
Sep 202210462
Oct 202211151
Nov 202210382
Dec 20229251
Jan 20236700
Feb 202313000
Mar 20235210
Apr 20237120
May 202311842
Jun 20233022
Jul 20236901
Aug 20238230
Sep 20238321
Oct 20235743
Nov 20237042
Dec 20239661
Jan 202414441
Feb 202410143
Mar 202411652
Apr 20247232
Total5787265144